BNGO

Bionano Genomics, Inc.

0.2382

Top Statistics
Market Cap 24 M Forward PE -0.4963 Revenue Growth -10.30 %
Current Ratio 1.63 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.3350 Enterprise / Revenue 0.8380 Price To Sales Trailing12 Months 0.6642
Profitability
Profit Margins 0.00 % Operating Margins -203.36 %
Balance Sheet
Total Cash 18 M Total Cash Per Share 0.2200 Total Debt 27 M
Total Debt To Equity 34.32 Current Ratio 1.63 Book Value Per Share 2.10
All Measures
Short Ratio 381.00 % Message Board Id finmb_5900432 Shares Short Prior Month 6 M
Return On Equity -1.38 City San Diego Uuid b62a5cf8-b7ae-336a-8f8b-f6a25125d0d8
Previous Close 0.2400 First Trade Date Epoch Utc 1 B Book Value 2.10
Beta 2.38 Total Debt 27 M Volume 2 M
Price To Book 0.1133 Last Split Date 1 B Fifty Two Week Low 0.2000
Total Cash Per Share 0.2200 Total Revenue 36 M Shares Short Previous Month Date 1 B
Target Median Price 1.00 Audit Risk 8 Max Age 86400
Recommendation Mean 3.00 Sand P52 Week Change 0.3133 Operating Margins -203.36 %
Target Mean Price 1.00 Net Income To Common -204100992 Short Percent Of Float 0.1026
Implied Shares Outstanding 101 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 3 M Average Volume10days 3 M Total Cash 18 M
Next Fiscal Year End 1 B Revenue Per Share 0.7490 Held Percent Insiders 0.0015
Ebitda Margins -249.93 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 0.2400
Target Low Price 1.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.3300
Open 0.2401 Free Cashflow -55978124 State CA
Dividend Yield 0.00 % Return On Assets -0.3264 Time Zone Short Name EST
Board Risk 7 Trailing Eps -2.30 Day Low 0.2318
Address1 9540 Towne Centre Drive Shares Outstanding 101 M Compensation Risk 10
Price Hint 4 Target High Price 1.00 Website https://www.bionano.com
52 Week Change -0.8491 Average Volume 2 M Forward Eps -0.4900
Recommendation Key hold Compensation As Of Epoch Date 1 B Quick Ratio 68.00 %
Last Split Factor 1:10 Regular Market Day High 0.2554 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 34.32 Fifty Two Week High 2.27
Day High 0.2554 Shares Short 9 M Regular Market Open 0.2401
Industry Key medical-instruments-supplies Earnings Growth 0.00 % Enterprise To Revenue 0.8380
Revenue Growth -10.30 % Shares Percent Shares Out 0.1025 Operating Cashflow -105181000
Currency USD Time Zone Full Name America/New_York Market Cap 24 M
Is_nasdaq_100 False Zip 92121 Quote Type EQUITY
Industry Medical Instruments & Supplies Long Name Bionano Genomics, Inc. Overall Risk 9
Regular Market Day Low 0.2318 Held Percent Institutions 0.1281 Current Price 0.2382
Address2 Suite 100 Enterprise To Ebitda -0.3350 Financial Currency USD
Current Ratio 1.63 Gross Margins 28.97 % Industry Disp Medical Instruments & Supplies
Number Of Analyst Opinions 1 Country United States Float Shares 81 M
Two Hundred Day Average 0.6966 Governance Epoch Date 1 B Enterprise Value 30 M
Price To Sales Trailing12 Months 0.6642 Forward PE -0.4963 Regular Market Volume 2 M
Ebitda -91420000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.

It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.

The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics.

In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing.

Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.